Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

SomnoMed Ltd

Healthcare AU SOM

0.63AUD
0.01(1.61%)

Last update at 2025-06-06T06:11:00Z

Day Range

0.560.63
LowHigh

52 Week Range

0.220.69
LowHigh

Fundamentals

  • Previous Close 0.62
  • Market Cap133.99M
  • Volume43740
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.54498M
  • Revenue TTM100.25M
  • Revenue Per Share TTM0.56
  • Gross Profit TTM 60.16M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Income before tax -11.27063M -7.04526M -3.49570M -0.73390M 0.75M
Minority interest - - - - -
Net income -12.24173M -7.99904M -4.43697M -1.19301M -1.11854M
Selling general administrative 18.01M 13.11M 12.62M 11.18M 10.05M
Selling and marketing expenses 26.18M 24.49M 19.74M 15.58M 15.44M
Gross profit 55.13M 45.77M 39.15M 33.90M 30.01M
Reconciled depreciation 5.78M 5.12M 3.94M 3.84M 3.09M
Ebit -8.10386M -4.41856M -3.11537M -0.26471M 1.22M
Ebitda -2.32861M 0.70M 0.82M 3.57M 4.31M
Depreciation and amortization 5.78M 5.12M 3.94M 3.84M 3.09M
Non operating income net other - - - - -
Operating income -8.32946M -4.07263M -4.13146M -0.65138M -0.94098M
Other operating expenses 95.49M 87.69M 76.71M 63.36M 58.24M
Interest expense 3.17M 2.63M 0.38M 0.47M 0.47M
Tax provision 0.97M 0.82M 0.93M 0.35M 1.19M
Interest income 0.03M 0.00201M 0.00043M 0.00395M 0.01M
Net interest income -3.13670M -2.62469M -0.37990M -0.46523M -0.30618M
Extraordinary items - -0.13214M -0.01066M -0.10995M -0.68023M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.97M 0.82M 0.93M 0.35M 1.19M
Total revenue 91.65M 83.62M 72.58M 62.71M 57.30M
Total operating expenses 63.46M 49.84M 43.28M 34.56M 30.96M
Cost of revenue 36.52M 37.85M 33.43M 28.80M 27.28M
Total other income expense net -2.94117M -2.97263M 0.64M -0.08252M -0.46240M
Discontinued operations - -0.13214M -0.01066M -0.10995M -0.68023M
Net income from continuing ops -12.24173M -7.86690M -4.42630M -1.08306M -0.43831M
Net income applicable to common shares - -7.99904M -4.43697M -1.19301M -1.11854M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 69.80M 62.49M 58.09M 56.17M 61.69M
Intangible assets - 12.48M 9.41M 2.32M 1.46M
Earning assets - - - - -
Other current assets 4.43M 0.32M 0.27M 0.13M 0.21M
Total liab 24.78M 40.09M 30.31M 24.01M 27.86M
Total stockholder equity 45.02M 22.40M 27.79M 32.16M 33.84M
Deferred long term liab - 9.67M 6.62M 1.25M 0.30M
Other current liab 4.05M 3.20M 11.18M 5.86M 10.50M
Common stock 110.23M 74.27M 74.27M 74.26M 73.94M
Capital stock - 74.27M 74.27M 74.26M 73.94M
Retained earnings -74.53666M -62.29494M -54.29589M -49.85891M -48.66591M
Other liab - 0.79M 1.18M 0.86M 0.83M
Good will 6.34M 6.49M 6.04M 6.26M 6.47M
Other assets - 3.25M 9.83M 4.37M 3.59M
Cash 16.18M 11.96M 15.64M 21.11M 30.17M
Cash and equivalents - 11.96M 15.64M 21.11M 30.17M
Total current liabilities 19.94M 18.36M 23.77M 16.20M 18.78M
Current deferred revenue 0.18M 0.00153M -6.65729M -1.95602M -7.57577M
Net debt -9.45907M 11.55M -3.63400M -12.20223M -14.64436M
Short term debt 2.60M 2.57M 6.66M 1.96M 7.28M
Short long term debt - 0.31M 4.88M - 4.95M
Short long term debt total 6.72M 23.51M 12.01M 8.91M 15.53M
Other stockholder equity 9.33M -21.76422M -29.76327M -34.20024M -35.39324M
Property plant equipment - 12.73M 9.12M 10.34M 10.24M
Total current assets 35.14M 27.50M 30.32M 34.13M 40.23M
Long term investments - - - - -
Net tangible assets - 13.10M 18.96M 24.83M 26.21M
Short term investments - - - - -
Net receivables 8.24M 8.71M 8.93M 8.09M 7.61M
Long term debt - 16.36M 2.01M 2.35M 2.51M
Inventory 6.29M 4.10M 3.09M 2.33M 2.24M
Accounts payable 13.11M 12.59M 12.59M 10.33M 8.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 10.43M 7.81M 7.76M 8.56M
Additional paid in capital - - - - -
Common stock total equity - - - - 73.94M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 13.97M -22.03566M -17.94336M -17.66934M 0.12M
Deferred long term asset charges - - - - -
Non current assets total 34.67M 35.00M 27.78M 22.04M 21.46M
Capital lease obligations - 6.84M 5.12M 6.56M 8.07M
Long term debt total - 20.94M 5.35M 6.95M 8.25M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -6.41458M 0.32M -0.27147M 0.31M 0.31M
Change to liabilities -1.88181M 2.34M 1.99M 0.68M 0.32M
Total cashflows from investing activities -6.41458M -8.47177M -4.36857M -1.82801M -1.63447M
Net borrowings 6.61M 2.09M -7.20332M 2.60M 2.44M
Total cash from financing activities 6.61M 2.09M -6.80435M 18.87M 2.38M
Change to operating activities 0.03M 0.70M 1.06M -0.34333M 1.25M
Net income -7.99904M -4.43697M -1.19301M -1.11854M -0.03939M
Change in cash -3.68792M -5.46551M -9.06440M 22.48M -5.68633M
Begin period cash flow 15.64M 21.11M 30.17M 7.70M 13.38M
End period cash flow 11.96M 15.64M 21.11M 30.17M 7.70M
Total cash from operating activities -3.88020M 1.86M 2.71M 5.19M -6.54714M
Issuance of capital stock - - 0.40M 16.88M 0.01M
Depreciation 3.97M 3.38M 3.29M 2.68M 1.45M
Other cashflows from investing activities 0.00000M 0.32M -0.23647M 0.36M 0.03M
Dividends paid - - - - 4.96M
Change to inventory -1.01080M -0.75944M -0.08770M -0.33884M 0.25M
Change to account receivables 0.37M -0.37342M -2.86074M 2.68M 2.64M
Sale purchase of stock 0.00000M 0.00000M 0.40M -0.61720M -0.07350M
Other cashflows from financing activities 12.95M 2.09M -7.20332M 2.60M 9.40M
Change to netincome 1.68M 0.46M -0.03839M 0.54M 3.14M
Capital expenditures 6.41M 8.79M 4.13M 2.19M 1.66M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.64406M -1.13286M -2.94844M 2.34M 0.04M
Stock based compensation 1.04M 1.19M 0.07M 0.42M -
Other non cash items 0.15M 2.92M 0.61M 3.63M 14.99M
Free cash flow -10.29479M -6.93064M -1.42633M 3.00M -8.20981M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SOM
SomnoMed Ltd		 0.01 1.61% 0.63 - - 1.34 2.89 1.24 40.34
COH
Cochlear Ltd		 -2.78 1.02% 268.49 48.10 38.76 7.68 9.45 7.58 29.32
PNV
Polynovo Ltd		 -0.03 2.24% 1.31 134.00 63.69 8.01 12.26 7.90 99.22
IMR
Imricor Medical Systems Inc		 -0.04 2.35% 1.66 - - 552.77 3.97 372.97 -2.6027
EBR
Ebr Systems Inc CDR		 0.06 4.96% 1.17 - - - 18.15 -3.6785

Reports Covered

Stock Research & News

View All

Profile

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.

SomnoMed Ltd

20 Clarke Street, Crows Nest, NSW, Australia, 2065

Key Executives

Name Title Year Born
Mr. Neil Verdal-Austin B.Com., C.A. Global CEO, MD & Director NA
Mr. Hervé Fiévet Global Chief Financial Officer NA
Mr. Mark Harding VP of Global Marketing NA
Mr. Matthew Conlon Exec. VP Sales & Marketing - North America NA
Mr. Marco Van Kleef VP of Marketing & Sales - Europe NA
Dr. Jagdeep Bijwadia Chief Medical Officer NA
Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., CA, SF FIN Company Sec. 1959
Dr. Peter Spencer MBA Ph.D., MAICD Gen. Mang. of Operations 1956
Mr. Christopher Bedford VP of Global Production and Product Devel. NA
Mr. Mark Harding Vice President of Global Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.